Biotech Startups

NunaBio manufactures high-complexity DNA constructs from challenging sequences up to production-scale volumes using a modular, cell-free "DNA micro-foundry" platform. It provides software-orchestrated, distributed DNA manufacturing infrastructure for producing complex DNA without process redevelopment.

5 investors

Nuritas uses a proprietary AI platform, the Nuritas Magnifier, to discover and clinically validate bioactive peptide ingredients derived from natural sources. It develops formulation-ready ingredients such as PeptiStrong for food, supplement, and health product companies.

5 investors

Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies. Its team spans chemistry, biology, translational and clinical development, and commercial functions supporting cancer drug programs.

5 investors

Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation. The company targets patients with chronic inflammatory and autoimmune conditions.

5 investors

Oculogica develops FDA-cleared concussion assessment devices that use proprietary eye-tracking technology to measure abnormal eye movements caused by traumatic brain injury. Its tools serve clinicians and athletic trainers across settings including sports sidelines, pediatric and urgent care clinics, accident/personal injury clinics, and military care.

5 investors

OlsAro develops climate-resilient cereal crops through gene editing and breeding technologies to improve crop yields and food security. The company partners with seed companies to commercialize traits that help farmers adapt to challenging environmental conditions like saline soils.

5 investors

Ona Therapeutics develops therapeutic antibodies targeting lipid metabolism to treat advanced and metastatic cancers, including liposarcoma. The company is a Spanish biotech firm focused on oncology with support from European and Spanish government research funding programs.

5 investors

One Zyme is an AI-native intelligence platform that aggregates scientific, clinical, regulatory, funding, patent, deal, and conference signals into a shared knowledge graph for life sciences teams. It provides AI agents and nine intelligence workflows serving business development, competitive intelligence, R&D, commercial, and biopharma vendor teams across the pharma and biotech industry.

5 investors

Ori Biotech develops manufacturing automation platforms for cell and gene therapies, addressing scalability and cost barriers that limit patient access to these treatments.

5 investors

Output builds generative AI models trained on biological data to discover and develop medicines. The company focuses on applying large biological models to improve diagnosis, treatment, and disease prevention.

5 investors

Pacifico Biolabs produces mycelium-based meat alternatives (branded Viando), starting with a chicken alternative made from fermented fungi, for food manufacturers and food service chains. It uses steel fermentation bioreactors to make its "mycomeat" as a B2B ingredient that integrates into existing meat supply chains and cooking processes.

5 investors

Panakeia develops software for biomarker profiling aimed at making precision diagnostics faster and instrument-free, to inform cancer diagnosis, treatment, and drug development. Its solutions target clinicians and researchers working in precision medicine and oncology.

5 investors

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

5 investors

Parallel Fluidics builds microfluidic products for life science teams, helping them move from concept to working device for applications like drug discovery and disease diagnostics. The company operates in the microfluidics and life science tooling space.

5 investors

Paterna Biosciences is developing a first-in-class biologic for reproductive biology using in vitro spermatogenesis technology. The company is advancing cell and gene therapy programs toward FDA approval.

5 investors

Pathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.

5 investors

Platform accelerating drug discovery for untreatable diseases.

5 investors

Peptone develops a product engine to design small-molecule drug candidates targeting intrinsically disordered proteins, which have been difficult to address with conventional drug discovery approaches.

5 investors

Perseus Proteomics develops and supplies research antibodies targeting nuclear receptors and transcription factors, along with ELISA kits and diagnostic assays, serving life sciences researchers and pharmaceutical development. The company provides approximately 100 antibody products including anti-ERβ antibodies established as the gold standard for ERβ research, as well as specialized antibodies for drug-antibody conjugates and radioimmunoterapy applications.

5 investors

A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.

5 investors

Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.

5 investors

PhenoTips develops software tools for genomic care that enable patients, doctors, and researchers to collaborate on diagnosis and treatment of genetic conditions. The platform supports rare disease patient matching and clinical genomic workflows.

5 investors

Pirouette develops OnePush, a fully automatic hidden-needle auto-injector platform paired with drug programs across chronic and rescue care indications. The company is advancing clinical-stage programs in naloxone, epinephrine, promethazine, and methotrexate while scaling U.S. automated manufacturing and securing IP protection through 2045.

5 investors

Planetary develops biomanufacturing facilities to enable sustainable, bio-based production at industrial scale. The company focuses on fermentation-based manufacturing for food and related industries.

5 investors